LY 215840

Drug Profile

LY 215840

Latest Information Update: 08 Dec 1998

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antiplatelets; Ergolines; Small molecules
  • Mechanism of Action Serotonin 2A receptor antagonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Migraine; Thrombosis

Most Recent Events

  • 08 Dec 1998 No-Development-Reported for Thrombosis in USA (Unknown route)
  • 15 Oct 1998 No-Development-Reported for Migraine in USA (Unknown route)
  • 13 Nov 1995 A clinical study has been added to the adverse events and pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top